Stryker Shares Slide 10% as Q3 Revenue, 2026 Guidance Miss Street Targets
Stryker Corp. (NYSE:SYK) reported Q3 revenue of $6.52B, missing estimates of $6.61B, and adjusted EPS of $3.52, below the $3.55 consensus. Shares fell 10.4% in pre-market trading. The company's 2026 guidance also fell short, with adjusted EPS projected at $14.80-$14.90, below the $14.95 consensus. CEO Kevin Lobo cited strong fundamentals but acknowledged the shortfall. Analysts lowered price targets but maintained Buy ratings.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered guidance are likely to keep the stock under pressure, though the new buyback could provide a floor.
Market read
The report is a primary earnings disclosure for a large‑cap med‑tech company, driving immediate price action and sector sentiment.
What to watch
Strong 9.2% growth in MedSurg segment and a $3B additional buyback authorization may support longer‑term upside.
Background
Stryker's Q3 results were released on Oct 30, 2026, with a notable 10% pre‑market decline.
Ticker impact
Stryker reported Q3 revenue of $6.52B and EPS of $3.52, both missing consensus, and lowered 2026 EPS guidance to $14.80‑$14.90, triggering a 10% share drop.
downward pressure as the market prices in the revenue and guidance miss
The miss on both top‑line and EPS, plus guidance below consensus, typically leads to further sell‑off beyond the initial 10% move.
Market effects
Medical‑technology sector may see broader weakness as peers are re‑rated on earnings expectations.
U.S. healthcare stocks could face short‑term pullback.
Limited to investors tracking large‑cap med‑tech names.
Counterpoint
If the market overreacts, the stock could rebound on the announced $4B buyback program.
Key entities
- personKevin A. Lobo
Chair and CEO of Stryker, quoted on performance and outlook.
